Article Information
History
- March 12, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Shutoku Matsuyama*,1,
- Miyuki Kawase1,
- Naganori Nao1,
- Kazuya Shirato1,
- Makoto Ujike2,
- Wataru Kamitani3,
- Masayuki Shimojima4 and
- Shuetsu Fukushi4
- 1Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan
- 2Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan
- 3Department of Infectious Diseases and Host Defense, Gunma University Graduate School of Medicine
- 4Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan
- ↵*To whom correspondence should be addressed: Shutoku Matsuyama, Ph.D, Department of Virology III, National Institute of Infectious Diseases, 4-7-1 Gakuen Musashi-Murayama, Tokyo 208-0011, Japan, tel 81-42-848-7065 ext3367, fax 81-42-567-5631, Email: matuyama{at}nih.go.jp
Posted March 12, 2020.
The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15
